Skip to main content
SpringerLink
Log in

Trastuzumab tallies up in HER2+ breast cancer

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Van Vlaenderen I, Canon J, Cocquyt V, Jerusalem G, Machiels J, Neven P, Nechelput M, Delabaye I, Glydmark M, Annemans L.Adjuvant trastuzumab treatment in early stage breast cancer: cost-effectiveness in the Belgian health care setting. Value in Health 10: A336 (plus poster) abstr. PCN44, No. 6, Nov-Dec 2007

  2. Chao TY, Chen SC, Chang KJ, Chang HK, Chen DR, Hou MF, Hsieh RK, Huang WT, Tseng LM, Wang HC, Yang L, Cirrincione A.Cost-effectiveness analysis of adjuvant trastuzumab for HER-2 positive early breast cancer in Taiwan. Value in Health 10: A327 (plus poster) abstr. PCN16, No. 6, Nov-Dec 2007

  3. Correa M, Perdicaris M, Vernaglia PRW, Da Cunha FM, Saggia MG, Santos EA, Nasciben V.Cost-effectiveness analysis of trastuzumab therapy in patients with early HER-2 positive breast cancer in Brazil. Value in Health 10: A327 (plus poster) abstr. PCN17, No. 6, Nov-Dec 2007

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trastuzumab tallies up in HER2+ breast cancer. Pharmacoecon. Outcomes News 541, 7 (2007). https://doi.org/10.2165/00151234-200705410-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200705410-00009

Keywords

Search

Navigation